Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of August 25th - 31st, 2023.

He begins by highlighting the EMA approval of pembrolizumab plus trastuzumab with chemotherapy as first-line treatment for HER2-positive gastric or gastroesophageal junction cancer, based on the progression-free survival data.

Dr Morgan also discusses an investigation of immune characteristics of non-small cell lung cancer patients with initial immune checkpoint inhibitor responses.

He concludes by reviewing the eight-year follow-up data post-trial, which shows the duration of adjuvant ovarian suppression added to tamoxifen in premenopausal women with hormone-receptor-positive breast cancer.

Follow Dr Morgan on twitter: @OncoAlert



Follow ecancer on twitter: @ecancer